Skip to main content

Table 1 Characteristics of studies included for meta-analysis

From: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Trial Design Cancer Enrollment size Anti-CTLA-4 Dose (mg/kg) CTC for AE version
Hodi [7] RCT, phase III Melanoma 676 Ipilimumab 3 3
Wilgenhof [14] Prospective observational study Melanoma 50 Ipilimumab 3 4
Delyon [15] Prospective observational study Melanoma 96 Ipilimumab 3 4
Margolin [16] Open label, phase II Melanoma 72 Ipilimumab 10 3
Hamid [17] Randomized, double blind, phase II Melanoma 82 Ipilimumab 3; 10 n/a
Danielli [18] Single arm, phase II Melanoma 13 Ipilimumab 10 3
Wolchok [19] Randomised phase II, dose ranging study Melanoma 217 Ipilimumab 0.3; 3; 10 3
O’Day [20] Multicenter, single arm, phase II Melanoma 155 Ipilimumab 10 3
Hersh [21] RCT, phase II Melanoma 74 Ipilimumab 3 2
Weber [22] Randomized, double blind, phase II Melanoma 115 Ipilimumab 10 3
Yang [23] Randomized, double blind, phase II, dose ranging study Renal cell 61 Ipilimumab 1; 3 n/a
Downey [24] Multicenter, single arm, phase II Melanoma 139 Ipilimumab 9 n/a
Ku [25] Compassionate use trial Melanoma 53 Ipilimumab 10 3
Di Giacomo [26] Single arm, phase II Melanoma 27 Ipilimumab 10 3
Royal [27] Single arm, phase II Pancreatic 27 Ipilimumab 3 3
Le DT [28] Randomized, open label, phase IB Pancreatic 30 Ipilimumab 10 3
Weber [29] Phase I/II Melanoma 88 Ipilimumab n/a n/a
Slovin [30] Non randomized, open label, multicenter, phase I/II Prostate 71 Ipilimumab 3; 5; 10 3
Calabro [31] Open label, single arm, phase II Mesothelioma 29 Tremelimumab 15 3
Chung [32] Multicenter, single arm, phase II Colorectal 47 Tremelimumab 15 3
Ralph [33] Single arm, phase II Gastric and esophageal 18 Tremelimumab 15 2
Ribas [34] Phase I Melanoma, renal cell, colon 39 Tremelimumab 10; 15 2
  1. CTC for AE version, Common Terminology Criteria for Adverse Events version; RCT, Research clinical trial; n/a, Non-available